All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes…
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1…
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire…
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,…
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon…
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care…
First-of-its-kind partnership between Aidoc and NVIDIA MONAI takes models from lab to scaled clinical use; new Quibim collaboration adds best-in-class Prostate…
VANCOUVER, BC / ACCESS Newswire / December 2, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech…